碘帕醇(Iopamidol) - 在研适应症：造影剂_专利_临床

概要

基本信息

药物类型

造影剂、小分子化药

别名

Iopamidol (JP17/USP)

+ [14]

靶点-

作用方式

增强剂

作用机制

射线照相增强剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Bayer Yakuhin Ltd.Bracco Diagnostics, Inc.Central Medical Service Co. Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1985-11-05),

造影剂

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H22I3N3O8

InChIKeyXQZXYNRDCRIARQ-LURJTMIESA-N

CAS号60166-93-0

关联

30

项与碘帕醇相关的临床试验

NCT06411795

/ Recruiting临床2期IIT

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

开始日期2023-11-10

申办/合作机构

University of Minnesota Masonic Cancer Center

[+1]

NCT05489055

/ Unknown statusN/A

Department of Radiology

Extrinsic prewarming of iodinated CT contrast media (CM) to body temperature reduces viscosity and injection pressures. However, guideline recommendations on the necessity to prewarm iodinated CM are conflicting. And studies examining the effect of extrinsic warming CM for coronary CTA(CCTA) on clinical adverse events and image quality are lack.
Enrolled patients of chest pain or coronary artery disease screening were eligible for this a double-blinded, randomized noninferiority trial, and equally allocated into two group randomly: BBT-CM (basic body temperature) group received 37°C CM; RT-CM (room temperature) group received
23°C CM. A state-of-the-art individualized CM (iopamidol at 370 mg I/mL) injection protocol was used, based on body weight.

开始日期2022-02-01

申办/合作机构

重庆市急救医疗中心（重庆市第四人民医院、重庆市急救医学研究所）

NCT05031520

/ Active, not recruitingN/AIIT

A Single Center Study of Perivascular Coronary Inflammation in Patients With Myocardial Ischemia or Infarction With Non-Obstructive Coronary Arteries

Among patients with ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Myocardial infarction (MI) with non-obstructive coronary artery disease (MINOCA) accounts for 5-20% of patients with MI and preferentially affects women. MINOCA pathogenesis is varied and may include atherosclerotic plaque rupture, plaque erosion with thrombosis, vasospasm, embolization, dissection or a combination of mechanisms. Other patients may have clinically unrecognized myocarditis, or takotsubo syndrome masquerading as MI. Among patients referred for coronary angiography for the evaluation of stable ischemic heart disease, non-obstructive CAD is present in up to
30% of men and
60% of women. Stable ischemia with non-obstructive coronary arteries (INOCA) may be due to coronary microvascular dysfunction in up to 40% of these patients. Our understanding of mechanisms of MINOCA and INOCA remain incomplete. Coronary inflammation has been hypothesized as a potential mechanism contributing to coronary spasm in MINOCA and microvascular disease in INOCA.

开始日期2021-07-12

申办/合作机构

NYU Langone Health

100 项与碘帕醇相关的临床结果

登录后查看更多信息

100 项与碘帕醇相关的转化医学

登录后查看更多信息

100 项与碘帕醇相关的专利（医药）

登录后查看更多信息

2,159

项与碘帕醇相关的文献（医药）

2025-06-01·Separation and Purification Technology

Constructing boron and oxygen dual coordination in g-C3N4 for robust catalytic ozonation and iopamidol degradation

作者: Yuan, Xiangjuan ; Sans, Carmen ; Liu, Jing ; Dong, Huiyu

In this study, a series of boron (B) and oxygen (O) dual doped g-C₃N₄ (BOCNx) composites with different boric acid dopant dosages were successfully synthesized through one-step thermal condensation method.Amongst, BOCN50 exhibited the best catalytic ozonation activity, achieving 97 % of iopamidol (IPM) degradation within 15 min and the highest k value (0.3166 min^-1), which was 8 times higher than that of ozonation alone.Multiple characteristic techniques were used to explore the surface properties of BOCNx catalysts and it was found that B and O primarily coordinated in g-C₃N₄ as the forms of C-O, C = O and B-N bonds.Further investigation in the structure-activity relationship of BOCNx catalyst indicated that the increasing contents of oxygen-containing functional groups and B-N bonds were linearly correlated with the IPM degradation rate.The results of scavenger experiments and ESR anal. demonstrated that the main reactive oxygen species involved were hydroxyl radicals, superoxide radicals, and singlet oxygen (^.OH, ^.O^-2 and ¹O₂).Addnl., up to 12 intermediate products of IPM during the reaction were detected, and the corresponding degradation pathways were elucidated.Finally, the structure of BOCN and the active sites for O₃ adsorption were determined by d. functional theory (DFT) calculation, thus providing theor. support for studying the mechanism of catalytic ozonation degradation

2025-05-01·Magnetic Resonance in Medicine

The proton resonance enhancement for CEST imaging and shift exchange (PRECISE) family of RF pulse shapes for CEST MRI

Article

作者: Stabinska, Julia ; McMahon, Michael T. ; Barker, Peter B. ; Gilad, Assaf A. ; Mohanta, Zinia

AbstractPurposeTo optimize a 100 ms pulse for producing CEST MRI contrast and evaluate in mice.MethodsA gradient ascent algorithm was employed to generate a family of 100 point, 100 ms pulses for use in CEST pulse trains (proton resonance enhancement for CEST imaging and shift exchange). Gradient ascent optimizations were performed for exchange rates = 500, 1500, 2500, 3500, and 4500 s−1; and labile proton offsets (Δω) = 9.6, 7.8, 4.2, and 2.0 ppm. Seven proton resonance enhancement for CEST imaging and shift exchange pulse shapes were tested on an 11.7 T scanner using a phantom containing three representative CEST agents with peak saturation B1,peak = 4 μT. The pulse producing the most contrast in phantoms was then evaluated for CEST MRI pH mapping of the kidneys in healthy mice after iopamidol administration.ResultsThe most promising pulse in terms of contrast performance across all three phantoms was the 9.6 ppm, 2500 s−1 optimized pulse with ˜2.7 × increase in asymmetric magnetization transfer ratio (MTRasym) over Gaussian, and ˜ 1.3 times over Fermi pulses for the same B1,peak = 4 μT. This pulse also displayed a large improvement in contrast over the Gaussian pulse after administration of iopamidol in live mice.ConclusionA new 100‐ms pulse was developed based on gradient ascent optimizations, which produced better contrast compared to standard Gaussian and Fermi pulses in phantoms. This shape also showed a substantial improvement for CEST MRI pH mapping in live mice over the Gaussian shape and appears promising for a wide range of CEST applications.

2025-05-01·Water Research

Transport model-based method for estimating micropollutant removal efficiency in riverbank filtration

Article

作者: Madarász, Tamás ; Pándics, Tamás ; Szűcs, Péter ; Erdélyi, Norbert ; Tóth, Andrea ; Vargha, Márta ; Fekete, Eszter ; Gere, Dóra ; Nyiri, Gábor ; Engloner, Attila ; Nagy-Kovács, Zsuzsanna Ágnes

Riverbank filtration is a cost-effective and efficient method for drinking water production, using the natural filtration capacity of the river gravelbed. Removal efficiency for organic micropollutants (OMP) in field studies is generally calculated by comparing the concentrations measured in surface water and in the wells either on the same day or with a shift of fixed time interval, neither of which can account for the variability of surface water quality and travel time in the aquifer. The present study proposes a novel method based on travel time distribution determined by a numerical transport model with a hypothesis that it will provide more reliable estimate for OMP removal. The model was developed for two production sites of Budapest Waterworks, Hungary on Danube River. River water and riverbank filtered well water were sampled regularly for one year (158 samples each) and analysed for 41 OMPs (pesticides, pharmaceutical residues and industrial pollutants). Nineteen pollutants were detected in >50 % of the well water samples. Median removal rates were 4-97 %, while the concentration of five compounds increased in some wells. Removal rates of telmisartan, tramadol, sulfamethoxazole, 4-methyl-benzotriazole, 5-methyl-benzotriazole and desethyl-terbuthylazine correlated negatively to redox potential (|r|=0.456-0.805). Median travel time increased after high flow events resulting in reduced removal of telmisartan, tramadol, 4-methyl-benzotriazole and desethyl-terbuthylazine (|r|= 0.435-0.661). Removal of diatrizoate, iopamidol, tramadol and benzotriazole increased with distance from the shore (148 vs 395 m) by 25 %, 28 %, 8 %, 16 %, respectively. Background groundwater contamination increased pesticide concentration in the wells located in agricultural areas 1.5-5-fold compared to river water. The model-based method gave more consistent results compared to traditional calculations for OMP removal efficiency during the sampling campaign and allowed for estimating the impact of various environmental factors.

143

项与碘帕醇相关的新闻（医药）

2025-03-07

·药智网

仿制药行业的「逆行者」

集采导致仿制药价格大幅下降，这对企业的营收构成了直接挑战。而倍特药业等仿制药重点企业，凭借其强大的研发实力和市场竞争力，在集采背景下依然保持了稳健的营收增长。数据显示，其药品制剂销售额持续增长，复合增长率高达30.7%，尤其在2021年实现了跨越式增长。 1 业绩斐然，稳健增长近年来，成都倍特药业的业绩持续增长，展现出强大的发展韧性与潜力。2023年，该企业药品制剂销售额达到74.10亿元。2016年-2023年期间，制剂销售额的复合增长率高达30.7%，尤其在2021年，倍特药业业绩实现跨越式增长，较2020年同比增长98.0%。注：上图统计了成都倍特药业股份有限公司、海南倍特药业有限公司的制剂产品销售情况。图1 倍特药业药品制剂销售额数据来源：药智数据，药智咨询整理倍特药业之所以取得如此优异的成绩，关键在于其多方面的科学规划与积极布局。企业深入洞察行业趋势与市场需求，为未来发展奠定了坚实基础。在研发投入上，倍特药业持续加大资金与人力投入，在披露的信息中，2017-2021年的研发投入占营收比例超过10%，巩固了现有产品的市场地位，更为企业开拓了新的增长点。而在市场拓展方面，倍特药业紧跟时代步伐，积极布局线上线下多元渠道，通过线上线下融合，构建起广泛且稳固的营销网络，有效提升了品牌知名度和市场占有率。这一系列科学规划与积极布局，共同推动了倍特药业的快速发展，使其取得了令人瞩目的成绩。下面我们看下倍特药业的产品布局和市场布局具体情况。 2 产品丰富，管线完备倍特药业构建了丰富多样的产品管线，广泛覆盖众多治疗领域，能够为患者提供全面的治疗方案。倍特药业研发实力强劲，近年来获批上市药物逐年增多，2024年有34个药物上市。目前已成功上市超20个首仿品种，如呋塞米口服溶液、利匹韦林片、达可替尼片等。图2 倍特药业获批上市产品数量情况图片来源：药智数据倍特药业上市产品涉及多个治疗领域，在系统用抗感染药布局最多，还布局血液和造血器官、消化系统及代谢、心脑血管系统、呼吸系统、神经系统等多个治疗领域。图3 倍特药业上市产品治疗领域情况图片来源：药智数据在造影剂板块，也有多款造影剂产品获批上市，包括钆贝葡胺注射液、碘克沙醇注射液、碘帕醇注射液等。表1 倍特药业造影剂领域布局情况注：2023年品种医院销售额指该品种所有厂家销售额。数据来源：药智数据，药智咨询整理与此同时，倍特药业积极投身创新药研发领域，研发管线布局涉及小核酸药物、抗体药物、细胞与基因治疗药物、核药等前沿方向，涵盖肿瘤、呼吸、妇产、心脑血管、代谢、神经等多个治疗领域。目前，多个创新药项目正在稳步推进，部分项目已取得阶段性关键成果，例如国内首款、全球第二款siRNA治疗转甲状腺素蛋白淀粉样变性新药-BPR-30221616注射液获批临床。这些创新药有望为企业未来的业绩增长提供强大动力。表2 倍特药业部分在研创新药数据来源：药智数据，药智咨询整理 3 掌控终端，模式多元倍特药业创新性地采用“掌控终端、模式多元”的混合营销模式，组建了制剂和原料药两大营销体系，其营销网络覆盖全国，并延伸至全球多个国家和地区。在院内市场方面，倍特药业积极参与国家组织的药品集中采购。从“4+7”试点到第十批“国家集采”，该企业先后有52个品种成功中选。在第十批国家组织药品集中采购中，倍特药业旗下公司共有15个药品中选，包括硫酸阿米卡星注射液、注射用哌拉西林钠、地高辛注射液等。表3 第十批国采倍特药业中标情况数据来源：药智数据，药智咨询整理此外，倍特药业还大力拓展线上销售渠道，与骁柔大健康等专业电商运营服务团队合作，开展全国范围内的线上电商业务，对抗感染、心脑血管、消化、代谢、儿科等多领域的数十款优势品种进行线上推广和销售。通过线上渠道，倍特药业能够触达更广泛的消费者群体，有效提升产品的知名度和销售额，进一步扩大市场份额。 4 结语站在新的发展起点上，成都倍特药业的未来充满无限可能。随着创新药研发的不断深入，倍特药业有望在重大疾病治疗领域取得更多突破性进展，推出更多具有自主知识产权的创新药物，为患者提供更多、更有效的治疗选择。凭借在产品研发、市场布局、团队建设等多方面积累的雄厚实力，成都倍特药业有望在未来书写更加辉煌的篇章。声明：本内容为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 斯蒂文合作、投稿、转载开白 | 马老师 18323856316（同微信）如需定制医药咨询服务，请扫描下方二维码咨询！阅读原文，是受欢迎的文章哦

带量采购核酸药物基因疗法上市批准

2025-03-05

·普利制药300630

普利制药美国客户与GPO Premier, Inc. 达成造影剂实质性战略合作

普利制药美国客户与GPO Premier, Inc. 达成造影剂实质性战略合作近日，普利制药的合作伙伴Slate Run Pharmaceuticals，与美国头部GPO Premier, Inc. 达成造影剂实质性战略合作。根据合作协议，Premier GPO 的成员可自行使用Premier预先签订的价格和条款来采购碘帕醇注射液、钆布醇注射液、钆特酸葡胺注射液和钆特醇注射液。普利制药预期未来可获得10%以上的市场份额，后续将拓展至更多造影剂品种。普利制药碘帕醇注射液美国ANDA（1）普利制药碘帕醇注射液美国ANDA（2）普利制药钆布醇美国ANDA 普利制药钆特酸葡胺美国ANDA 普利制药钆特醇美国ANDA 1 美国GPO 美国GPO（Group Purchasing Organization，药品集中采购组织）是一个将各种医疗机构或其他医疗服务提供者的购买需求进行集中的组织，它利用组织内部成员的集体购买力，通过与供应商谈判以帮助各成员寻求更低的购买价格和折扣。与国内充分竞争的情况不同，美国造影剂市场准入门槛高，竞争格局好。目前，在美国碘帕醇注射液市场上普利制药是唯一一家供货的仿制药企业。普利制药的钆特醇注射液是美国首家且目前唯一获批的仿制药。此外，钆布醇注射液市场仅有3家（含原研），钆特酸葡胺注射液仅有4家（含原研）参与竞争。此次与美国头部GPO的合作，预期未来可以迅速打开美国的造影剂市场。 FDA官网显示：美国碘帕醇注射液市场上普利制药是唯一一家供货的仿制药企业 FDA官网显示：普利制药的钆特醇注射液是美国首家且目前唯一获批的仿制药 3 普利制药在普利制药的国际化布局中，造影剂是一个重点业务领域。普利制药拥有包含钆特酸葡胺、钆特醇、钆布醇、碘帕醇、碘佛醇等多个成品制剂，并且采用原料制剂一体化策略，进行全球注册和销售，已经达成碘帕醇注射液、钆特酸葡胺注射液、钆布醇注射液、钆特醇注射液的美国获批和钆布醇注射液的荷兰获批；实现碘帕醇注射液、钆特酸葡胺注射液的中国获批。未来，普利制药将一如既往地以“先进高端制造,面向国际和国内双循环”的战略，持续不断地推出更多更好的药物供应全球，为患者提供高品质的药物。欢迎有兴趣海外拓展的同行，抱团出海！业务联系人：周先生邮箱：zm@hnpoly.com 诚邀国际开拓的精英加盟，欢迎联系HR凌女士！ hnpolyhr@hnpoly.com

医药出海上市批准

2025-02-20

·普利制药300630

【喜讯】安徽普利原料药伏立康唑荣膺欧盟CEP认证，诚邀您共谋发展，共铸辉煌未来！

【喜讯】安徽普利原料药伏立康唑荣膺欧盟CEP认证，诚邀您共谋发展，共铸辉煌未来！ Join us to grow and shine bright 共谋发展，共铸辉煌未来海南普利制药股份有限公司（以下简称“普利制药”）控股子公司安徽普利药业有限公司（以下简称“安徽普利”）已于近日收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，已下简称“EDQM”）签发的原料药伏立康唑欧洲药典适用性认证（以下简称“CEP”）证书。本次伏立康唑CEP证书的获得，表明该原料药符合欧洲药典的质量要求，显示欧洲规范市场对该原料药质量的认可和肯定。为安徽普利进一步拓展国际市场带来积极影响。 PART.01 产品基本情况 1、产品基本情况介绍伏立康唑是一种三唑类抗真菌药物，通过抑制真菌中由细胞色素P450介导的14α-甾醇去甲基化，从而抑制麦角甾醇的生物合成。对曲霉菌属、丝状菌、念珠菌、各种酵母菌均具有杀菌作用，具有高效、广谱、组织分布广、吸收利用率高，易透过深部组织等特点。是临床用于预防、治疗可能威胁生命的真菌感染患者的一线首选药物。注射用伏立康唑由辉瑞公司研发，于2002年3月获欧洲药物管理局（EMA）批准上市，2002年5月获美国食品药品监督管理局（FDA）批准上市，2004年10月获国家药品监督管理局批准上市，商品名为VFEND（威凡）。 2、市场情况根据IMS数据显示，中国和美国分别是全球伏立康唑注射剂产出第一和第五的市场，分别占比57%和3%。在中国市场，普利制药注射用伏立康唑在第八批国家药品集中采购中选，并凭借其卓越的品质和稳定的供应能力保持市场份额的稳健增长。与此同时，公司在海外市场坚定不移地实施全球化战略，通过不断拓展和深化其海外市场布局，使得海外上市许可批件的数量持续增长，实现众多成果“落地生金”，至此已取得占全球份额65%的市场准入资格。 3、质量优势 1）产品质量好，与参比制剂一致; 2）产品符合ChP、EP、USP等多方药典标准; 3）有专用生产线，可以稳定供货; 4) 年产能吨级以上。 4、注册法规优势安徽普利伏立康唑原料药产品已在中美欧等市场进行原料药备案/登记，高品质原料药满足各级市场注册、生产、销售需求。 ①其中US DMF号为038466（状态：A ）; ②CN登记号为Y20230000941 (状态: I ）； ③CEP证书号：CEP 2023-327- Rev 00 ,符合欧洲药典的质量要求；其他市场的注册工作也在持续推进中。伏立康唑辅料磺丁基-β-环糊精钠，已在中美欧等市场进行辅料备案/登记/，递交注册申报资料： ① CN登记号为F20220000553，(与制剂共同审评审批结果: A）； ② US DMF号为037814，（状态：A）； ③ 欧洲证明编号：CEP 2022-504-Rev 00；其他市场的注册工作也在持续推进中。这也将为未来普利制药伏立康唑注射剂稳定且持续供应并服务于全球客户奠定坚实基础。 PART.02 合作共赢安徽普利将利用自身产品优势，发挥国际注册的能力（已经在多国注册，并且有丰富的国际注册经验），借助国际化制造、质量控制体系和成熟的国际化市场开拓能力，愿与有志于开拓此产品的国内、国际制剂客户提供全方位、深度合作，共创未来。 PART.03 安徽普利安徽普利药业有限公司坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利目前拥有10条符合欧美中GMP标准的API 生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、熊去氧胆酸、依克多因、红景天苷等）、抗肿瘤（BPA、环磷酰胺等）、其他原料药（盐酸多巴酚丁胺、硝普钠、氢氧化镁、阿普斯特、克立硼罗、伏立康唑、格隆溴铵、盐酸美金刚、特考韦瑞、阿昔洛韦钠、更昔洛韦钠、布美他尼、氟康唑、二硫化硒、别嘌醇等）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙钠等）等系列产品的研发与生产。欢迎垂询、欢迎合作！ Welcome for enquiry, cooperation！联系人：Faye Xue 电话：13616530509 邮箱：ff@hnpoly.com 联系人：Ruowei Li 电话：18720526102 邮箱：liruowei@hnpoly.com

上市批准医药出海

100 项与碘帕醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01797	碘帕醇	V08AB04	DB08947

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
造影剂	日本	Bayer Yakuhin Ltd.	1985-11-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	申请上市	美国	Bracco Diagnostics, Inc.	2007-11-01
冠状动脉狭窄	申请上市	美国	Bracco Diagnostics, Inc.	2007-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04504331 (CTgov)	临床1期	PR 阳性乳腺癌 \| HER2 阴性乳腺癌 \| ER阳性乳腺癌 \| HR阳性/HER2阴性乳腺癌	4	Omnipaque 350+Tamoxifen+Infigratinib+Iopamidol (Cohort 1: Infigratinib (100mg) + Tamoxifen)	憲繭簾繭鑰築鏇蓋鹽築(壓窪簾遞憲鏇淵積夢積) = 鹹夢襯願襯淵鏇鑰鹽夢糧廠築鏇網鑰獵夢觸繭 (築膚襯觸製夢膚製壓窪, 鹽鬱蓋淵襯築鑰遞鑰製 ~ 製餘淵鑰壓簾糧觸簾糧) 更多	-	2023-06-01
				Omnipaque 350+Tamoxifen+Infigratinib+Iopamidol (Cohort 2: Infigratinib (125mg) + Tamoxifen)	憲繭簾繭鑰築鏇蓋鹽築(壓窪簾遞憲鏇淵積夢積) = 廠夢醖簾鬱獵範鏇憲構糧廠築鏇網鑰獵夢觸繭 (築膚襯觸製夢膚製壓窪, 淵願鑰鏇齋鹹淵糧網築 ~ 衊網網築餘觸齋糧餘觸) 更多
NCT02433665 (CTgov)	N/A	造影剂	166	Iopamidol (Fixed Dose)	鑰鏇膚製簾襯夢壓鹽膚(襯廠簾糧鏇蓋鹹襯顧鬱) = 鹹獵廠餘積壓醖構膚簾艱鹽憲鹽鏇壓鹽範艱夢 (鏇鹽蓋膚壓範廠膚艱範, 築鬱艱鬱衊餘鹽壓選襯 ~ 衊蓋簾簾鏇蓋蓋衊鹽鹹) 更多	-	2020-06-16
				Mydose+Iopamidol (Customized Dose)	鑰鏇膚製簾襯夢壓鹽膚(襯廠簾糧鏇蓋鹹襯顧鬱) = 淵顧襯餘積鬱膚網鑰簾艱鹽憲鹽鏇壓鹽範艱夢 (鏇鹽蓋膚壓範廠膚艱範, 齋鬱襯繭鬱選構網鑰壓 ~ 鹹鬱選鏇鏇願簾顧艱壓) 更多
NCT02467075 (CTgov)	临床4期	宫颈上皮内瘤样病变 \| 急性肾损伤	1	Iopamidol 300 (Contrast) (Iopamidol 300 (Contrast))	醖觸壓鏇艱壓鹽鹽構鹽(顧鬱範膚繭鏇齋遞艱鏇) = 築製鹽網壓範構願鬱觸構鏇繭醖窪鏇觸齋鏇鏇 (觸蓋範遞鹹製繭網網餘, 範願憲艱積淵醖範廠鹽 ~ 繭鏇蓋廠鹽夢鏇獵鹹選) 更多	-	2017-06-27
				Placebo (Normal Saline) (Placebo (Normal Saline))	醖觸壓鏇艱壓鹽鹽構鹽(顧鬱範膚繭鏇齋遞艱鏇) = 襯築簾壓夢夢廠網艱餘構鏇繭醖窪鏇觸齋鏇鏇 (觸蓋範遞鹹製繭網網餘, 醖鏇顧衊夢淵餘艱鬱艱 ~ 醖鑰糧鑰願鹹艱艱遞餘) 更多
NCT02170688 (CTgov)	临床4期	造影剂	139	Isovue 370 (Fixed Dose)	顧遞網積網鑰鹽襯餘鏇(觸壓醖淵艱顧膚網夢築) = 蓋製壓廠醖糧製糧鏇積壓糧構獵鹹顧顧齋蓋齋 (觸積壓顧鹽製網艱廠夢, 鏇鹹夢糧壓廠築構遞網 ~ 蓋鏇繭鏇網窪糧膚獵淵) 更多	-	2014-12-12
				Weight calculation+Isovue 370 (Total Body Weight)	顧遞網積網鑰鹽襯餘鏇(觸壓醖淵艱顧膚網夢築) = 遞鏇鏇壓憲築選廠醖觸壓糧構獵鹹顧顧齋蓋齋 (觸積壓顧鹽製網艱廠夢, 醖衊膚淵夢鏇餘艱構製 ~ 夢壓鏇鹽艱廠願選壓觸) 更多
NCT00209417 (CTgov)	临床4期	糖尿病 \| 肾功能不全	656	Iodixanol 320-Arm 1 (Iodixanol 320-Arm 1)	糧廠範鬱醖範淵繭憲糧(餘鬱糧衊蓋餘鏇鹹齋餘) = 蓋觸獵壓遞構鏇淵鬱簾廠鹽鬱艱憲構觸顧襯範 (觸鏇範鏇鑰網顧淵醖繭, 簾醖窪鬱積鹹襯夢築餘 ~ 繭範鬱襯蓋願衊網襯範) 更多	-	2014-10-10
				Iopamidol 300-Arm 2 (Iopamidol 300-Arm 2)	糧廠範鬱醖範淵繭憲糧(餘鬱糧衊蓋餘鏇鹹齋餘) = 壓廠鏇構顧積夢範憲壓廠鹽鬱艱憲構觸顧襯範 (觸鏇範鏇鑰網顧淵醖繭, 選鏇襯網襯餘壓餘顧積 ~ 繭糧選顧繭鬱繭鹽願壓) 更多
NCT02171247 (CTgov)	临床3期	-	35	Visipaque 320 (Visipaque 320)	觸夢艱鬱範憲鬱簾蓋構(壓廠顧顧艱顧築糧繭範) = 繭鹽願鹹憲膚鬱齋衊襯網齋憲淵遞觸糧膚窪襯 (鹽製顧膚窪襯醖鏇鹹夢, 鏇鑰積鏇鑰選壓顧簾餘 ~ 糧鹹糧壓蓋範夢遞鹽襯) 更多	-	2014-08-15
				Isovue 370 (Isovue 370)	觸夢艱鬱範憲鬱簾蓋構(壓廠顧顧艱顧築糧繭範) = 構淵鏇繭製築衊構網艱網齋憲淵遞觸糧膚窪襯 (鹽製顧膚窪襯醖鏇鹹夢, 簾範顧夢繭夢鑰構壓鬱 ~ 鏇觸衊獵獵餘築鬱顧衊) 更多
NCT01136876 (CTgov)	临床4期	终末器官损害 \| 冠状动脉狭窄	57	iodixanol 320 (Iodixanol 320 Serum NGAL)	顧糧選鑰襯鑰鑰觸鑰繭(範築襯膚淵艱鑰築積範) = 製鏇齋廠製網壓遞齋廠願鏇積鏇積遞鏇襯夢獵 (選壓艱製醖鬱齋齋構醖, 衊顧鬱襯鏇壓選憲築餘 ~ 壓選鏇鬱遞壓選糧衊築) 更多	-	2013-12-30
				iodixanol 320 (Iodixanol 320 Urine NGAL)	顧糧選鑰襯鑰鑰觸鑰繭(範築襯膚淵艱鑰築積範) = 繭積願齋獵鹽範願壓壓願鏇積鏇積遞鏇襯夢獵 (選壓艱製醖鬱齋齋構醖, 鬱廠鏇鏇築廠憲鬱鑰選 ~ 願選願膚網夢構鑰壓窪) 更多
NCT00558792 (CTgov)	临床2期	冠心病 \| 冠状动脉狭窄	210	Isovue 370, 70 mL (Isovue 370, 70 mL)	觸構鹹醖蓋願廠構鹹選(範醖膚餘製餘遞選構構) = 鹹鹹築衊憲網觸築遞蓋觸遞範網鏇觸鑰餘鑰壓 (蓋淵夢齋衊廠願願觸膚, 鏇壓醖襯鏇選餘壓鬱範 ~ 選衊壓襯願膚膚鹽艱窪) 更多	-	2012-10-19
				Isovue 370, 80 mL (Isovue 370, 80 mL)	觸構鹹醖蓋願廠構鹹選(範醖膚餘製餘遞選構構) = 糧獵夢膚廠鏇襯遞窪艱觸遞範網鏇觸鑰餘鑰壓 (蓋淵夢齋衊廠願願觸膚, 鏇獵糧醖餘製襯廠醖網 ~ 築衊範艱膚淵糧積窪齋) 更多
NCT00740207 (CTgov)	临床4期	疼痛 \| 外周动脉闭塞性疾病	33	Isovue 250 (ISOVUE 250)	鹽構廠膚積鹹齋糧蓋醖(繭鹹蓋遞糧夢鹹膚網鏇) = 繭夢窪齋網構糧製顧鬱衊襯壓願廠構築鏇顧襯 (網淵製鑰夢窪襯蓋廠艱, 鏇廠構鹽選顧齋顧網觸 ~ 廠糧艱築夢壓糧淵鏇築) 更多	-	2011-04-18
				VISIPAQUE 270 (VISIPAQUE 270)	鹽構廠膚積鹹齋糧蓋醖(繭鹹蓋遞糧夢鹹膚網鏇) = 夢範鏇襯壓構鑰構製憲衊襯壓願廠構築鏇顧襯 (網淵製鑰夢窪襯蓋廠艱, 繭願廠淵淵蓋壓鑰醖憲 ~ 憲窪餘願繭繭憲網膚遞) 更多